FDA places partial clinical hold on Bright Minds' BMB-101 Phase 2 DEE seizure trial
The hold, tied to toxicity seen in mice, halts development of the epilepsy candidate and cut Bright Minds' share price in half.
Read at Biopharmadive →Full coverage · 14 outlets
- Biopharmadive · lead
- Fierce BiotechFDA dims Bright Minds’ outlook with partial hold on seizure trial over toxicity in mice
- AllSciBright Minds' Phase II DEE seizure trial blocked by FDA partial clinical hold on BMB-101
- Yahoo FinanceUniQure gets an FDA decision date; Teva scraps brain drug study
- scanx.tradeFDA places partial clinical hold on Bright Minds' BMB-101 trial
- DealroomFDA places partial clinical hold on Bright Minds' BMB-101 Phase 2 epilepsy trial
- Mugglehead Investment MagazineBright Minds Biosciences reports FDA partial hold on BMB‑101 seizure trial
- StreetInsiderFDA places Bright Minds Biosciences BMB-101 trial on partial hold
- Stock TitanThe FDA put Bright Minds' planned seizure study partly on hold, citing toxicity findings in mice.
- The Clinical Trial VanguardBright Minds’ BMB-101 Hold Exposes a Recurring Failure in Preclinical-to-IND Translation
- Seeking AlphaBright Minds Biosciences: Downgrade To 'Hold' On BMB-101 Setback DEE And Progression Into PWS
- Laurel Leader-CallBright Minds Biosciences Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Bright Minds Biosciences (DRUG)
- TipRanksFDA places clinical hold on Bright Minds BMB-101-105 IND application
- MSNFDA puts partial hold on Bright Minds’ Phase II seizure study